- Home
- ENTA vs MPLN Comparison
ENTA vs MPLN Comparison
Compare ENTA & MPLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- MPLN
- Stock Information
- Founded
- ENTA 1995
- MPLN 1980
- Country
- ENTA United States
- MPLN United States
- Employees
- ENTA N/A
- MPLN N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- MPLN Business Services
- Sector
- ENTA Health Care
- MPLN Consumer Discretionary
- Exchange
- ENTA Nasdaq
- MPLN Nasdaq
- Market Cap
- ENTA 127.8M
- MPLN 110.0M
- IPO Year
- ENTA 2013
- MPLN N/A
- Fundamental
- Price
- ENTA $6.28
- MPLN $6.01
- Analyst Decision
- ENTA Buy
- MPLN Hold
- Analyst Count
- ENTA 4
- MPLN 2
- Target Price
- ENTA $19.50
- MPLN $25.00
- AVG Volume (30 Days)
- ENTA 537.1K
- MPLN 68.4K
- Earning Date
- ENTA 02-05-2025
- MPLN 11-05-2024
- Dividend Yield
- ENTA N/A
- MPLN N/A
- EPS Growth
- ENTA N/A
- MPLN N/A
- EPS
- ENTA N/A
- MPLN N/A
- Revenue
- ENTA $67,635,000.00
- MPLN $942,614,000.00
- Revenue This Year
- ENTA $11.80
- MPLN N/A
- Revenue Next Year
- ENTA $3.99
- MPLN $1.17
- P/E Ratio
- ENTA N/A
- MPLN N/A
- Revenue Growth
- ENTA N/A
- MPLN N/A
- 52 Week Low
- ENTA $5.70
- MPLN $4.80
- 52 Week High
- ENTA $17.80
- MPLN $69.20
- Technical
- Relative Strength Index (RSI)
- ENTA 31.04
- MPLN 36.08
- Support Level
- ENTA $5.70
- MPLN $6.64
- Resistance Level
- ENTA $6.56
- MPLN $7.40
- Average True Range (ATR)
- ENTA 0.74
- MPLN 0.67
- MACD
- ENTA -0.11
- MPLN -0.02
- Stochastic Oscillator
- ENTA 14.91
- MPLN 2.37
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.